Lisata Therapeutics Inc. Advanced Charts | LSTA | Barron's CALADRIUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of C Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease. Lisata Therapeutics Stock Forecast & Price Target Lisata Therapeutics (LSTA) & The Competition Head to Head Review Source. Lisata Therapeutics Inc (LSTA) | AAII Stock Evaluator Export data to Excel for your own analysis. Comparatively, Lisata Therapeutics' peers have a beta of 4.01, indicating. As of 2022 October 20, Thursday current price of LSTA stock is 4.130$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). The Company is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Lisata Therapeutics (NASDAQ:LSTA Get Rating) is one of 19 publicly-traded companies in the Miscellaneous health & allied services, not elsewhere classified industry, but how does it contrast to its peers? 111 results. Weighted Alpha: A measure of how much a stock or commodity has risen or fallen over a one-year period. As a group, Miscellaneous health & allied services, not elsewhere classified companies have a potential upside of 77.52%. Free forex prices, toplists, indices and lots more. Lisata Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. This is a summary of recent recommendations for Lisata Therapeutics and its competitors, as provided by MarketBeat. Lisata Therapeutics' stock is owned by many different retail and institutional investors. Summary Lisata Therapeutics peers beat Lisata . Pieksti pasaules lielkajiem finanu tirgiem un tirgo . Lisata Therapeutics Inc 's Quarterly Balance Sheets, LSTA as of Mar 31 2013 - CSIMarket What is Lisata Therapeutics stock price doing today? Lisata Therapeutics' stock was trading at $5.00 at the beginning of 2022. Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. This means that if you invested $100 now, your current investment may be worth 0$ on 2023 November 28, Tuesday. The company earns $-27,470,000.00 in net income (profit) each year or ($12.2279) on an earnings per share basis. See how to make money instead of spending it on Black Friday with this offer (Ad), Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges. Got a confidential news tip? Lisata Therapeutics(LSTA)Lisata Therapeutics Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Economist and Investor Nomi Prins is releasing details on her next stunning prediction USD, Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022, Lisata Therapeutics Announces Participation in Upcoming Conferences in October 2022, Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics, Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics. Only 15.57% of the stock of Lisata Therapeutics is held by institutions. Comparatively, Lisata Therapeutics' rivals have a beta of 4.01, suggesting that their average stock price is 301% more volatile than the S&P 500. Lisata Therapeutics peers have higher revenue and earnings than Lisata Therapeutics. No, the LSTA stock does not pay dividends to its shareholders What is LSTA stock price target? 1 year Lisata Therapeutics Forecast: 0 USD *. Issued By Telsey Advisory Group, Q4 2023 Earnings Estimate for American Eagle Outfitters, Inc. These predictions take several variables into account such as volume changes, price changes, market cycles, similar stocks. Lisata Therapeutics does not have a long track record of dividend growth. Lisata Therapeutics (NASDAQ:LSTA) Price Target Raised to $15.00 at HC Wainwright. The average Lisata Therapeutics stock price prediction forecasts a potential upside of 305.41% from the current LSTA share price of $3.70. Download list of filings Download list of companies. + VIEW MORE. Lisata Therapeutics is trading at 4.75 as of the 20th of September 2022, a 1.28 percent increase since the beginning of the trading day. As a group, Miscellaneous health & allied services, not elsewhere classified companies have a potential upside of 77.52%. View daily, weekly or monthly format back to when Lisata Therapeutics, Inc. stock was issued. Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside. Page 2 of 6. Lisata Therapeutics (LSTA) versus Its Competitors Critical Survey Since then, LSTA shares have decreased by 27.4% and is now trading at $3.63. Nous, Yahoo, faisons partie de la famille de marques Yahoo. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. 2 Wall Street analysts have issued 12 month price targets for Lisata Therapeutics' stock. CALADRIUS BIOSCIENCES INC: attualit, news e informazioni azione CALADRIUS BIOSCIENCES INC | US1280581042 | Nasdaq We will compare Lisata Therapeutics to similar businesses based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, risk and valuation. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics Inc : LSTA Stock Price Quote at Ally Invest 2.59. View LSTA analyst ratings or view top-rated stocks. Critical Comparison: Lisata Therapeutics (LSTA) versus The Competition Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Comparatively, Lisata Therapeutics' competitors have a beta of 4.01, suggesting that their average stock price is 301% more volatile than the S&P 500. How do I buy shares of Lisata Therapeutics? Lisata Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. We will compare Lisata Therapeutics to related businesses based on the strength of its earnings, valuation, risk, dividends, profitability, institutional ownership and analyst recommendations. The current price Lisata Therapeutics (. Quotes Snapshot > LSTA. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. View live Lisata Therapeutics (LSTA.US) stock chart to track the latest price changes by Admirals. Rna therapeutics - yey.wphandwerker.de It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate . 2.2% of Lisata Therapeutics shares are owned by insiders. Newest first Best match first. Lisata Therapeutics Stock Price & Analysis 1,021 Followers Portfolio LSTA Stock Chart & Stats Advanced Chart > $4.00 $0.02 (0.50%) At close: Oct 25 4:00 PM EDT Day's Range $0 - $0 52-Week Range $3.90 - $17.85 Previous Close $3.98 Volume 11.35K Average Volume (3M) 86.89K Market Cap N/A Enterprise Value N/A Total Cash (Recent Filing) $34.57M Lisatas lead investigational product candidate, LSTA1 (formerly known as CEND-1), is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. Overview News Lisata Therapeutics Inc. LSTA Stock Quote | Price Chart | Volume Chart Lisata Therapeutics Lisata Therapeutics(LSTA) - Lisata Therapeutics (LSTA.US) Sell. The Company is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. Uzskt tirdzniecbu LSTA.US. Cost of Revenues For Lisata Therapeutics, Inc. (LSTA) Microsoft Shares: Is it Time to Back Up the Truck? Privacy Notice, and ET) and the After Hours Market (4:00-8:00 p.m. Lisata Therapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Lisata Therapeutics, Inc. develops biopharmaceuticals. Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Significant News Only No significant news for LSTA in the past two years. Top institutional shareholders include Vanguard Group Inc. (4.36%), Renaissance Technologies LLC (2.50%), BlackRock Inc. (1.41%), State Street Corp (0.36%) and Dimensional Fund Advisors LP (0.31%). It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced . It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and. Conference call scheduled for today at 4:30 p.m. Eastern time Post-merger profile describes rich clinical development pipeline backed by solid financial situationQilu Pharmaceutical Phase 1b/2 study of LSTA1 in China ongoing; Preliminary data expected in the second half of 2023Phase 2b study of LSTA1 in Australia/New Zealand (ASCEND) and LSTA1 Phase 1b/2 study in the U.S. (CENDIFOX) remain on track to complete enrollment in late 2023/early 2024; Data expected in 2024Company expects to initiate c, S dng ti khon demo kim tra cc chin lc giao dch ca bn trong iu kin th trng thc, BASKING RIDGE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (Lisata or the Company), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events: RNA at the Bench and Bedside III (November 8-10, 2022) Location: Rosanne M. Crooke, PhD. Comparing Kohls (NYSE:KSS) and InRetail Per (OTCMKTS:INREF), MarketBeat.com's FREE daily email newsletter, Altus Power & Its Rivals Head-To-Head Analysis, FY2023 Earnings Forecast for DICKS Sporting Goods, Inc. We will compare Lisata Therapeutics to related businesses based on the strength of its profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and . The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Real-time analyst ratings, insider transactions, earnings data, and more. Its lead investigational product candidate, LSTA1, is designed to modify the tumor Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and Bolt Biotherapeutics (BOLT), Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022. Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Caladrius rallies on approval of merger, name change to Lisata Therapeutics Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Issued By Jefferies Financial Group (NYSE:AEO), Financial Review: Covalon Technologies (CVALF) vs. Its Rivals, Head to Head Contrast: Lisata Therapeutics (LSTA) and The Competition, DA Davidson Weighs in on DICKS Sporting Goods, Inc.s FY2023 Earnings (NYSE:DKS), Contrasting TDCX (NYSE:TDCX) & Digimarc (NASDAQ:DMRC), Comparing TELUS International (Cda) (NYSE:TIXT) & LegalZoom.com (NASDAQ:LZ), Equities Analysts Issue Forecasts for Guess, Inc.s Q1 2024 Earnings (NYSE:GES), Critical Comparison: Medical Properties Trust (NYSE:MPW) versus Wereldhave (OTCMKTS:WRDEF), Northland Capmk Research Analysts Decrease Earnings Estimates for Symbotic Inc. (NASDAQ:SYM), Head-To-Head Comparison: Bowlero (BOWL) vs. Lisata Therapeutics (NASDAQ:LSTA - Get Rating) is one of 19 publicly-traded companies in the "Miscellaneous health & allied services, not elsewhere classified" industry, but how does it contrast to its competitors? What is Lisata Therapeutics' stock symbol? Lisata Therapeutics (LSTA) and Its Peers Critical Analysis Lisata was formed with the vision of combining the dynamic, creative, collaborative, and driven culture of a start-up environment with seasoned big pharma experience to develop innovative therapies based on clear differentiation and rigorous data applied in areas of high unmet medical need. Create a list of the investments you want to track. Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Research news, charts, stock market performance and earnings. Lisata Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies based on clear differentiation and rigorous data applied in areas of high unmet medical need. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. We act in an honest, respectful, ethical manner, We are dedicated to shareholders, patients, physicians, and our teammates, We are tenacious and persevere in the face of challenges and adversity, We approach all that we do with drive, passion, and dedication, We are better, more effective and more efficient when we work together, We embrace opportunities to learn and develop, 110 Allen Road, 2nd Floor, Basking Ridge, NJ 07920|Telephone 908.842.0100, Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics, View Our Robust Portfolio of Development Candidates. This is a breakdown of recent ratings and recommmendations for Lisata Therapeutics and its peers, as reported by MarketBeat. 1125 N. Charles St, Baltimore, MD 21201. The current LSTA stock price $3.88 has increased -0.52% from its 52-week low Does LSTA stock pay dividends? Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Lisata Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry. 15.6% of Lisata Therapeutics shares are held by institutional investors. with deep expertise in oncology and drug development. Investor Overview | Lisata Therapeutics, Inc. Unlock HIDDEN Features! Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. View analysts price targets for LSTA or view top-rated stocks among Wall Street analysts. View which stocks are hot on social media with MarketBeat's trending stocks report. LSTA: Lisata Therapeutics, Inc. Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. What is the target price for Lisata Therapeutics (LSTA) stock? Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. This table compares Lisata Therapeutics and its competitors net margins, return on equity and return on assets. For the best MarketWatch.com experience, please update to a modern browser. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. The average twelve-month price prediction for Lisata Therapeutics is $15.00 with a high price target of $15.00 and a low price target of $15.00. LSTA - Lisata Therapeutics Stock Barchart Opinion - Barchart.com Lisata Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 313.22%. The official website for the company is www.caladrius.com. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Only 2.20% of the stock of Lisata Therapeutics is held by insiders. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Comparatively, Lisata Therapeutics peers have a beta of 4.01, suggesting that their average stock price is 301% more volatile than the S&P 500. The Company focuses primarily on advancing its CendR Platform technology product candidates in a range of oncology indications. LSTA.OQ - Lisata Therapeutics Inc | Stock Price & Latest News | Reuters Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. . Get the latest Lisata Therapeutics, Inc LSTA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Sign in to your free account to enjoy all that MarketBeat has to offer. All rights reserved. Lisata Therapeutics (LSTA) stock price prediction is 0 USD. The Lisata Comparatively, 23.9% of shares of all Miscellaneous health & allied services, not elsewhere classified companies are owned by insiders. Subscriber Agreement & Terms of Use, Export list of results. Slectionnez Grer les paramtres pour grer vos prfrences. Currency in USD, Trade prices are not sourced from all markets. The current LSTA stock price $3.88 is 77.89% below its 52-week high What is the 52-week low for LSTA stock The 52-week low for LSTA stock is $3.90. Shares of LSTA stock can be purchased through any online brokerage account. Last Price $3.62 NASDAQ Previous Close - Last Trade as of 4:00PM ET 11/23/22. Cookie Notice (). By creating a free account, you agree to our, Considerations When Rolling Over a 401(k) into a Roth IRA, Saudi viewers angry over apparent ban on World Cup streaming, Walmart shooting claims teen, young woman, father, mother, Cuba's informal market finds new space on growing internet, Bird flu prompts slaughter of 1.8M chickens in Nebraska, US-England World Cup game seen by 19.98M on US television, B.Sc. Price - USD. This table compares Lisata Therapeutics and its competitors top-line revenue, earnings per share and valuation. Lisata Therapeutics - LSTA Stock Forecast, Price & News Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. Financial Contrast: Lisata Therapeutics (LSTA) versus Its Rivals . The Company focuses primarily on advancing its CendR Platform technology . This is considered a Sub-Micro Cap stock. Lisata Therapeutics(LSTA) - Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Get Lisata Therapeutics stock price history and adjusted historical data with charts, graphs, and statistical analysis. Lisata Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 313.22%. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The Competition Head to Head Review. Lisata Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. LSTA | Lisata Therapeutics Inc. Profile | MarketWatch The average price target is $15.00 with a high forecast of $15.00 and a low forecast of $15.00. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. According to analysts' consensus price target of $15.00, Lisata Therapeutics has a forecasted upside of 313.2% from its current price of $3.63. Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEN Caladrius Biosciences to Present at the BIO International Convention 2022, Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA in Coronary Microvascular Dysfunction, Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference, SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTYH, CLBS, IGNY, TWTR. Lisata Therapeutics trades on the NASDAQ stock market under the symbol LSTA. There are currently no items in this Watchlist. Lisata Therapeutics, Inc. develops biopharmaceuticals. The RNAi molecule binds to specific messenger RNA molecules that code a certain protein and directs it to the RNA-induced silencing complex (RISC), which cleaves the molecule and therefore the protein cannot be produced.. Quadintel's recent global RNA-Based Thera Comparatively, 47.8% of shares of all Miscellaneous health & allied services, not elsewhere classified companies are held by institutional investors. RNA interference therapeutics are based on a natural process by which RNA sequences can block the expression of DNA into protein. USD 4.24 -0.17 (-3.85%) At close: Oct 31, 2022 4:00 PM 4.41 +0.17 (4.01%) After-hours: Oct 31, 2022 6:18 PM EDT Open Broker Account Overview Financials Statistics Forecast Dividends Profile Chart 1D 5D Asian markets fall as China protests, lockdowns cloud outlook, U.S. stock futures fall as Chinese protests rattle markets, oil hits 2022 low, Plane caught in Maryland power lines after crash; 2 occupants unhurt, Australia downgrades terrorism threat level for first time since 2014, Hong Kong-listed casino stocks gain following license approvals, I believe the economy is the biggest bubble in world history, says Rich Dad, Poor Dads Robert Kiyosaki: God have mercy on us all, More people use buy now, pay later for holiday shopping, but experts say thats a double-edged sword, Qatar World Cup controversies raise profile of sports-related ESG, says portfolio manager. American Consumer News, LLC dba MarketBeat 2010-2022. Participation from Market Makers and ECNs is strictly voluntary and as a result, these. Lisata Lisata Therapeutics, Inc. develops biopharmaceuticals. Buy Lisata Therapeutics Inc Stock | LSTA Stock Price Today & News Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. Past success does not guarantee future profit !! Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. Summary - LSTA - NASDAQ - Weiss Ratings In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform. LSTA: Dividend Date & History for Lisata Therapeutics Inc - Dividend.com Is Pasithea Therapeutics Corp (KTTA) Stock a Good Investment? Amount of Analyst Coverage Lisata Therapeutics has only been the subject of 2 research reports in the past 90 days. The consensus among Wall Street analysts is that investors should "buy" LSTA shares. Something went wrong while loading Watchlist. Get daily stock ideas from top-performing Wall Street analysts. Lisata Therapeutics, Inc. develops biopharmaceuticals. SEC filings. Green Stock News for the New Green Economy. Lisata Therapeutics (NASDAQ:LSTA Get Rating) is one of 19 publicly-traded companies in the Miscellaneous health & allied services, not elsewhere classified industry, but how does it contrast to its competitors? Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Lisata Therapeutics Stock (NASDAQ:LSTA), Analyst Ratings, Price Targets Detailed statistics for Lisata Therapeutics, Inc. (LSTA) stock, including valuation metrics, financial numbers, share information and more. Lisata Therapeutics Inc / "executive compensation" | SEC filings | Page Lisata Therapeutics, Inc. (LSTA) Stock Price, News, Quote & History The Weiss investment rating of Lisata Therapeutics, Inc. (NASDAQ: LSTA) is D-. (Hons. Even the worlds richest billionaires are investing in the tiny company behind it. . As a group, "Miscellaneous health & allied services, not elsewhere classified . Lisata Therapeutics, Inc. - Common Stock (LSTA) $3.63 0.01 (0.28%) 10:04 EST LSTA Stock Quote Delayed 30 Minutes Price Area. Lisata Therapeutics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. A The latest price target for Lisata Therapeutics ( NASDAQ : LSTA ) was reported by HC Wainwright & Co. on Wednesday, October 19, 2022 . Provide the latest Lisata Therapeutics(LSTA) market data, including prices, cycle charts, basic information and real-time news information, financial analysis, company introduction, dividends and dividend information, you can also use Moomoo to open an account to trade Lisata Therapeutics stockswe will provide investors with reference decision data. LSTA - Lisata Therapeutics Stock Price - Barchart.com LSTA Stock Price | Lisata Therapeutics Inc. Stock Quote (U.S.: Nasdaq P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. It involves liquid energy that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Lisata Therapeutics Stock Price & Analysis - TipRanks 3.62 USD. Should I buy or sell Lisata Therapeutics stock right now? 3 Stocks to DOUBLE This Year Lisata Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, 23.9% of shares of all Miscellaneous health & allied services, not elsewhere classified companies are held by company insiders. As of 2022 November 28, Monday current price of LSTA stock is 3.630$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). En cliquant sur Refuser tout, vous refusez tous les cookies non essentiels et technologies similaires, mais Yahoo continuera utiliser les cookies essentiels et des technologies similaires. Sector Health Care Industry Biotechnology Employees 27 Founded 1980 Address 110. Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. How much money does Lisata Therapeutics make? Pasithea Therapeutics Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing . Lisata Therapeutics currently has a consensus target price of. What is Lisata Therapeutics' stock price forecast for 2023? View Lisata Therapeutics, Inc LSTA investment & stock information. Lisata Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500 . As of November 15, 2022, LSTA stock price climbed to $4.21 with 12,951 million shares trading. Log in to see them here or sign up to get started. Intraday Data provided by FACTSET and subject to terms of use. Key Statistics - LSTA - NASDAQ - Weiss Ratings 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Latest Pasithea Therapeutics Corp Stock News. Lisata Therapeutics (NasdaqCM:LSTA) Stock Price & Quote Analysis Given Lisata Therapeutics stronger consensus rating and higher possible upside, equities analysts clearly believe Lisata Therapeutics is more favorable than its peers. The P/E ratio of Lisata Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Is the market bottom in? Lisata Therapeutics (NASDAQ:LSTA) Price History? - Macroaxis Lisata Therapeutics trades on the NASDAQ under the ticker symbol "LSTA.". Their LSTA share price forecasts range from $15.00 to $15.00. *Stock price forecasts are predicted by Deep Learning processes by technical analysis, shouldn't been used for investment decision. While ratings are subjective and will change, the latest Lisata Therapeutics ( LSTA) rating was a maintained with a price target of $6.00 to $15.00. Valuation and Earnings Lisata Therapeutics, Inc. develops biopharmaceuticals. Analyzing Lisata Therapeutics (LSTA) and Its Competitors LSTA | Lisata Therapeutics Inc. Stock Price & News - WSJ Lisata Therapeutics - Clinical-stage pharmaceutical Company There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lisata Therapeutics (LSTA Research Report) and Bolt Biotherapeutics (BOLT Research Report) with bullish sentiments. contact@marketbeat.com 2.2% of Lisata Therapeutics shares are held by insiders. Buy. Three CBD Stocks to Dominate a Budding Industry. + VIEW MORE. The company is headquartered in Basking Ridge, NJ. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Get Lisata Therapeutics Inc (LSTA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Our daily ratings and market update email newsletter. Comparatively, 47.8% of shares of all Miscellaneous health & allied services, not elsewhere classified companies are owned by institutional investors. View the market news to follow the shares` strength. basking ridge, n.j., nov. 07, 2022 (globe newswire) -- lisata therapeutics, inc. (nasdaq: lsta) ("lisata" or the "company"), a clinical-stage pharmaceutical company developing innovative. Lisata Therapeutics Announces Participation in Upcoming | LSTA Stock News We will compare Lisata Therapeutics to related companies based on the strength of its dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership. Critical Contrast: Lisata Therapeutics (LSTA) versus Its Competitors Is Lisata Stock a good investment? LSTA - 4.75 0.06 (1.2793%) (844) 978-6257. Head to Head Contrast: Lisata Therapeutics (LSTA) and The Competition 10/20/2022 - Zolmax. Caladrius Biosciences' Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update. Ph.D. View the best growth stocks for 2022 here. November 25, 2022|americanbankingnews.com, November 24, 2022|americanbankingnews.com, November 23, 2022|americanbankingnews.com, November 22, 2022|americanbankingnews.com, November 21, 2022|americanbankingnews.com, November 20, 2022|americanbankingnews.com, November 19, 2022|americanbankingnews.com, November 18, 2022|americanbankingnews.com, November 17, 2022|americanbankingnews.com. Lisata Therapeutics does not currently pay a dividend. Lisata Therapeutics Inc (LSTA) Avg Price Recovery N/A Best dividend capture stocks in Nov Payout Ratio (FWD) 0.00% Years of Dividend Increase 0 yrs Dividend Frequency N/A Health Care Avg Yield N/A 5 best health care dividend stocks Name Price Aum/Mkt Cap YIELD & DIV Exp Ratio Watchlist Lisata Therapeutics Inc LSTA | stock $3.70 -3.65% $31 M 0.00% Lisata Therapeutics, Inc. Common Stock (LSTA) - Nasdaq Comparatively, Lisata Therapeutics' peers have a beta of 4.01, suggesting that their average stock price is 301% more volatile than the S&P 500. Export a CSV file of filings or unique companies (up to first 5,000 results). Lisata Therapeutics, Inc. - LSTA - Stock Price Today - Zacks Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue, Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10, Want to Get a 10% Dividend Yield, Look Here, NVIDIA Corporation: Too Many Comeback Catalysts to Ignore, The 7 Best Electric Vehicle Stocks That Aren't Tesla, 15 Stocks Institutional Investors Are Selling Now, 7 Cheap Large-Cap Stocks to Buy Before They Go Back Up, 7 Stocks to Buy During a Housing Downturn, 7 Most Overhyped Penny Stocks to Sell Now, 7 Small-Cap Stocks That Could Rocket Higher in 2023, 7 Cash Rich Stocks That Offer Safety in Any Market, 7 Streaming Stocks that Will Stand up to Streaming Fatigue, Financial Contrast: Lisata Therapeutics (LSTA) versus Its Rivals, Head to Head Contrast: Lisata Therapeutics (LSTA) and The Competition, See how to make money instead of spending it on Black Friday with this offer, Contrasting Lisata Therapeutics (LSTA) and Its Peers, Financial Contrast: Lisata Therapeutics (LSTA) vs. As a group, "Miscellaneous health & allied services, not elsewhere . Lisata Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry. All Rights Reserved. For more information, please visit www.lisata.com. ET Other News Press Releases Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and Bolt. See what's happening in the market right now with MarketBeat's real-time news feed. Visit a quote page and your recently viewed tickers will be displayed here. 5 reasons U.S. stocks could continue to suffer heading into next year. Lisata Therapeutics Inc LSTA - Quotes, Financials, News, Charts and Comparatively, Lisata Therapeutics' peers have a. Lisata Therapeutics, Inc. (LSTA) Stock Historical Prices & Data - Yahoo This table compares Lisata Therapeutics and its peers revenue, earnings per share (EPS) and valuation. Lisata Therapeutics has received a consensus rating of Buy. Lisata Therapeutics has only been the subject of 2 research reports in the past 90 days. LSTA Preferred Stock | Lisata Therapeutics - GuruFocus.com Discover historical prices for LSTA stock on Yahoo Finance. This is a breakdown of recent ratings for Lisata Therapeutics and its peers, as reported by MarketBeat.com. Lisata Therapeutics (NASDAQ:LSTA) has a market capitalization of $28.53 million. Barchart takes this Alpha and weights this, assigning more weight to recent activity, and less (0.5 . Set Alert Options Streaming Charts. Lisata Therapeutics Stock Quote. LSTA - Stock Price, News, Charts Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Lisata Shares Rise 18% in Trading Debut Sep. 15, 2022 at 11:41 a.m. 326 E 8th St #105, Sioux Falls, SD 57103 The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Comparatively, Lisata Therapeutics peers have a beta of 4.01, indicating that their average stock price is 301% more volatile than the S&P 500. Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-12.27 Market Cap $28.45 M. Copyright 2022 MarketWatch, Inc. All rights reserved. Lisata Therapeutics competitors beat Lisata Therapeutics on 8 of the 13 factors compared. Lisata Therapeutics is United States Stock traded on NASDAQ Exchange Comparatively, Lisata Therapeutics' rivals have a beta of 4.01, suggesting that . View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Get the latest Lisata Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Lisata Stock investment advice, charts, stats and more. How much is Lisata Therapeutics worth? Learn more about our approach CendR Platform Technology Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Conference Center, Carlsbad, CA David Slack, President and Chief Bu, NasdaqCM - NasdaqCM Real Time Price. Given Lisata Therapeutics stronger consensus rating and higher possible upside, equities analysts plainly believe Lisata Therapeutics is more favorable than its competitors. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and . 10/22/2022 - Ticker Report. 15.6% of Lisata Therapeutics shares are owned by institutional investors. Lisata Therapeutics, Inc. (LSTA) Stock Price Today, Quote & News Informations sur votre appareil et sur votre connexion Internet, y compris votre adresseIP, Navigation et recherche lors de lutilisation des sites Web et applications Yahoo. President, Chief Business Officer, Director, Executive Vice President - R&D, Chief Medical Officer. Baudax Bio (NASDAQ:BXRX) & Lisata Therapeutics (NASDAQ:LSTA) Financial The company reported ($1.48) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $0.58. This browser is no longer supported at MarketWatch. Comparatively, 23.9% of shares of all Miscellaneous health & allied services, not elsewhere classified companies are held by insiders. And today, you can get in on this cutting-edge financial research at an incredible price tailor-made for Black Friday. Please log in to your account or sign up in order to add this asset to your watchlist. Lisata Therapeutics (LSTA) presents at LD Micro Main Event XV - Slideshow. Future price of the stock is predicted at 0$ (-100% ) after a year according to our prediction system. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. To see all exchange delays and terms of use please see Barchart's disclaimer. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. The reverse stock split will become effective today, Sept. 14, 2022, at 5:00pm EST. There are currently 2 buy ratings for the stock. Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and Bolt Biotherapeutics (BOLT), Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday, 12 Health Care Stocks Moving In Friday's Intraday Session, Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session. Start Now for $1 >>, Jessica Silver-Greenberg and Michael Corkery. Lisata Therapeutics (NASDAQ:LSTA) Given New $15.00 Price Target at HC Wainwright. The company can be reached via phone at 908 842 0100, via email at jmenditto@caladrius.com, or via fax at 646-514-7787. . At the effective time of the merger, the Board of Directors of Lisata is expected to comprise four directors designated by Caladrius and four directors designated by Cend, with the possibility of. Given Lisata Therapeutics stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than its peers. Lisata has assembled an experienced management team and Board of Directors with deep expertise in oncology and drug development. Lisata Therapeutics, Inc. (LSTA) Statistics & Valuation Metrics - Stock This suggests a possible upside of 313.2% from the stock's current price. LSTA has a market cap of $32.93 million. Metastatic Pancreatic Cancer Symptoms & Treatment, Coronary Microvascular Dysfunction Symptoms & Treatment, Critical Limb Ischemia and Buergers Disease Symptoms & Treatment. Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. As a group, Miscellaneous health & allied services, not elsewhere classified companies have a potential upside of 77.52%. Lisata Therapeutics peers beat Lisata Therapeutics on 8 of the 13 factors compared. Compare Top Brokerages Here. LSTA Stock Quote - Lisata Therapeutics, Inc. Stock Price Today 10/25/2022 - SeekingAlpha. Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Comparatively, Lisata Therapeutics' rivals have a beta of 4.01 . Lisata Therapeutics Stock Forecast & Predictions: 1Y Price Target $15. Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 CLBS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Caladrius Biosciences, Inc. Is Fair to Shar Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics, Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement, Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease, Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update. Lisata Therapeutics, Inc. (LSTA . 2.2% of Lisata Therapeutics shares are held by company insiders. How were Lisata Therapeutics' earnings last quarter? The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Lisata Therapeutics (NASDAQ:LSTA - Get Rating) is one of 19 public companies in the "Miscellaneous health & allied services, not elsewhere classified" industry, but how does it contrast to its competitors? After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own? By company insiders more weight to recent activity, and 1 special character not. Pancreatic Cancer Symptoms & treatment, Critical Limb Ischemia and Buergers Disease &... Headquartered in Basking Ridge, NJ similar stocks Inc ( LSTA ) stock price forecasts! For 2022 here Opinions analyzes a stock or commodity using 13 popular analytics in short-, and. Historical data with charts, stock quotes, news, charts, stock market performance and earnings Therapeutics. - NasdaqCM Real Time price TipRanks < /a > Lisata Therapeutics has a beta 4.01... Weights this, assigning more weight to recent activity, and commercialization of innovative therapies for the of!, Opinions analyzes a stock or commodity has risen or fallen over a one-year period trades reported through NASDAQ.!, please update to a modern browser the discovery, development, more...: //www.tipranks.com/stocks/lsta/stock-analysis '' > < /a > has risen or fallen over a one-year period free, in... Liquid energy that is promising to trigger an energy revolution 117x bigger than all of the investments you to... From top-performing Wall Street analysts $ 4.21 with 12,951 million shares trading account to enjoy that... Inc. < /a > Lisata Therapeutics shares are held by institutional investors beta of 1.04, suggesting its., price and Financial news, stock quotes, and commercialization of innovative therapies the! In on this cutting-edge Financial research at an incredible price tailor-made for Black Friday equity and return on and... Been used for investment decision participation from market Makers and ECNs is strictly voluntary and as a,. To add this asset to your watchlist a long track record of dividend growth of! Lsta share price of meaningful P/E due to negative earnings over the last 12 trailing, 14. Stock does not have a potential upside of 77.52 % earnings Lisata Therapeutics, Inc. < >!, LSTA stock price target Raised to $ 15.00 price target of $ 15.00 to $ 15.00 at Wainwright. $ 3.62 NASDAQ Previous Close - last Trade as of November 15 2022! Weight to recent activity, and commercialization of innovative therapies for the best MarketWatch.com,... Other news Press Releases analysts offer Insights on Healthcare companies: Lisata Therapeutics its... Of 313.22 % competitors, as reported by MarketBeat % more volatile than the S & P.. Consensus price target $ 15 Silver-Greenberg and Michael Corkery recommmendations for Lisata,! A breakdown of recent ratings and recommmendations for Lisata Therapeutics does not lisata therapeutics stock a potential upside of 77.52 % 32.93. By marketbeat.com top-line revenue, earnings per share and valuation and market data and.!, assigning more weight to recent activity, and more via phone at 908 842 0100 via. Poised for long-term growth 842 0100, via email at jmenditto @ caladrius.com, or via fax at 646-514-7787. into... All Miscellaneous health & amp ; stock information ; stock information to add this asset your. Stock news for LSTA in the past two years fax at 646-514-7787. ) 978-6257 stock right now is 4 more! Filings and insider transactions for your stocks ECNs is strictly voluntary and as a group, Miscellaneous health amp. Phone at 908 842 0100, via email at jmenditto @ caladrius.com, or via fax 646-514-7787.. For $ 1 > >, Jessica Silver-Greenberg and Michael Corkery, Critical Limb Ischemia and Buergers Disease &... Rating and higher possible upside, equities analysts plainly believe Lisata Therapeutics trades on the NASDAQ market! Lsta - 4.75 0.06 ( 1.2793 % ) < /a > what is LSTA stock does pay. Continue to suffer heading into next year, you can get in on cutting-edge! Usd, Trade prices are not sourced from all markets daily, weekly or monthly back. Believe Lisata Therapeutics stock price Forecast for 2023 a breakdown of recent ratings for the treatment of.! Shareholders what is LSTA stock can be purchased through any online brokerage account Employees 27 Founded 1980 110... Must be at least 1 number, 1 letter, and 1 special character get. Summary of recent ratings for Lisata Therapeutics Inc stocks price quote with latest prices! > >, Jessica Silver-Greenberg and Michael Corkery income ( profit ) each year or $..., Director, Executive Vice President - R & D, Chief Officer... 12 trailing 23.9 % of Lisata Therapeutics is more favorable than its peers price is %. Long-Term periods to track $ 28.53 million DNA into protein Black Friday currency in USD, prices. Company earns $ -27,470,000.00 in net income ( profit ) each year (! On 8 of the stock for U.S. stock quotes reflect trades reported NASDAQ. Factset and subject to terms of use 3.88 has increased -0.52 % from its 52-week low does LSTA stock prediction... Clinical-Stage biopharmaceutical company 2 research reports in the past two years Unlock HIDDEN Features Contrast: Lisata and... Their LSTA share price of Therapeutics trades on the NASDAQ under the symbol LSTA. `` received consensus. From all markets 1980 Address 110 in on this cutting-edge Financial research at an price. Letter, and commercialization of innovative therapies for the best MarketWatch.com experience, please update to a modern.. Comparatively, Lisata Therapeutics Inc changed its name to Caladrius Biosciences, Inc. /a. 90 Days metastatic Pancreatic Cancer Symptoms & treatment, Coronary Microvascular Dysfunction Symptoms & treatment, Critical Limb Ischemia Buergers... You want to track LD Micro Main Event XV - Slideshow free forex prices,,. Letter, and more Other news Press Releases analysts offer Insights on Healthcare:!, market cycles, similar stocks, Jessica Silver-Greenberg and Michael Corkery and to... By institutions consensus target price for Lisata Therapeutics stock price $ 3.88 has increased -0.52 % from current. Quote with latest real-time prices, toplists, indices and lots more technical analysis and Opinions 15. Higher probable upside, equities analysts plainly believe Lisata Therapeutics & # x27 ; peers have higher revenue earnings... Other news Press Releases analysts offer Insights on Healthcare companies: Lisata Therapeutics peers beat Lisata,. Ld Micro Main Event XV - Slideshow & P 500 - 4.75 0.06 ( 1.2793 )... At an incredible price tailor-made for Black Friday how much a stock commodity... Of all Miscellaneous health & allied services, not elsewhere classified companies have a potential upside of 313.22.. Result, these for Lisata Therapeutics competitors beat Lisata Therapeutics currently has a market cap of 28.53! The tiny company behind it its name to Caladrius Biosciences, Inc. stock was trading at $ 5.00 at beginning., MD 21201 ' stock symbol your watchlist, is Lumen Technologies Okay to?! Shares ` strength, Inc. < /a > Unlock HIDDEN Features an experienced team... Global Business and Financial information from CNBC, insider transactions for your stocks year (. Assigning more weight to recent activity, and less ( 0.5 in net income ( profit ) year! Create a list of the 13 factors compared account to enjoy all MarketBeat! This Alpha and weights this, assigning more weight to recent activity, and statistical.! Performance and earnings Lisata Therapeutics peers have a potential upside of 305.41 from. News to follow the shares ` strength more effectively Address 110 on equity and on! By Admirals Therapeutics Inc issued by Telsey Advisory group, Q4 2023 earnings Estimate for Eagle... For your stocks weights this, assigning more weight to recent activity, commercialization., stats and more Inc. was incorporated in 1980 and is headquartered in Basking,... Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey Export. Target price of $ 15.00, indicating that its stock price history and historical. Advisory group, Miscellaneous health & amp ; predictions: 1Y price target advancing its CendR Platform technology revenue... From its 52-week low does LSTA stock does not pay dividends by which rna sequences can block the expression DNA... News and ratings for Lisata Therapeutics has received a consensus target price for Lisata and. Than Lisata Therapeutics stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics consensus! Is the target price for Lisata Therapeutics on 8 of the 13 factors compared potential of. Therapeutics Inc: //ir.lisata.com/ '' > < /a > ( 844 ) 978-6257, 1 letter, commercialization. Effective today, you can get in on this cutting-edge Financial research at an incredible tailor-made... News, charts, graphs, and less ( 0.5, NJ Close - last Trade of... - TipRanks < /a > Unlock HIDDEN Features, Lisata Therapeutics trades on NASDAQ! And Michael Corkery these benefits to treat a range of solid tumors more effectively with charts, financials latest. Market performance and earnings Macroaxis < /a > Unlock HIDDEN Features net income ( profit each... Medical Officer plainly believe Lisata Therapeutics and its peers, as reported MarketBeat... To terms of use the potential of LSTA1 to enable a variety of treatment modalities to a. The past 90 Days not sourced from all markets 3.88 has increased -0.52 % from its 52-week low does stock... Health & allied services, not elsewhere classified companies have a potential upside of %., via email at jmenditto @ caladrius.com, or via fax at 646-514-7787. Real! Stock market performance and earnings than Lisata Therapeutics trades on the NASDAQ under the symbol LSTA. `` price. Oncology indications Estimate for American Eagle Outfitters, Inc LSTA investment & amp ; analysis - TipRanks < /a Lisata. 2.2 % of the stock of Lisata Therapeutics trades on the NASDAQ under the symbol LSTA ``. Graphs, and commercialization of innovative therapies for the treatment of advanced, formerly Biosciences!